MaaT's therapeutic restores functional microbiome in AML patients

MaaT Pharma S.A. (Lyon, France) said its MaaT Microbiome Restoration Biotherapeutic (MMRB) was well tolerated and led to functional microbiota restoration in the Phase Ib/IIa ODYSSEE trial in patients at risk for dysbiosis.

In 25 patients with acute myelogenous leukemia (AML) who had undergone intensive chemotherapy and multiple courses of antibiotics, the autologous fecal microbiota transplantation restored more than 90% of the microbial species diversity and structure in the gut at day 40, and reduced by 43% the overall expression of antibiotic resistance genes. MMRB also reduced gut inflammation to near-baseline levels as measured by the fecal biomarker neopterin...